JP2023534131A5 - - Google Patents
Info
- Publication number
- JP2023534131A5 JP2023534131A5 JP2022577750A JP2022577750A JP2023534131A5 JP 2023534131 A5 JP2023534131 A5 JP 2023534131A5 JP 2022577750 A JP2022577750 A JP 2022577750A JP 2022577750 A JP2022577750 A JP 2022577750A JP 2023534131 A5 JP2023534131 A5 JP 2023534131A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024187587A JP2025020197A (ja) | 2020-07-22 | 2024-10-24 | 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055026P | 2020-07-22 | 2020-07-22 | |
| US63/055,026 | 2020-07-22 | ||
| EP20192414 | 2020-08-24 | ||
| EP20192414.9 | 2020-08-24 | ||
| US202163156988P | 2021-03-05 | 2021-03-05 | |
| US63/156,988 | 2021-03-05 | ||
| PCT/EP2021/070485 WO2022018186A1 (en) | 2020-07-22 | 2021-07-22 | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024187587A Division JP2025020197A (ja) | 2020-07-22 | 2024-10-24 | 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023534131A JP2023534131A (ja) | 2023-08-08 |
| JPWO2022018186A5 JPWO2022018186A5 (https=) | 2024-07-24 |
| JP2023534131A5 true JP2023534131A5 (https=) | 2024-07-24 |
| JP7581385B2 JP7581385B2 (ja) | 2024-11-12 |
Family
ID=77179985
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022577750A Active JP7581385B2 (ja) | 2020-07-22 | 2021-07-22 | 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 |
| JP2024187587A Pending JP2025020197A (ja) | 2020-07-22 | 2024-10-24 | 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024187587A Pending JP2025020197A (ja) | 2020-07-22 | 2024-10-24 | 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20220177538A1 (https=) |
| EP (1) | EP4185607A1 (https=) |
| JP (2) | JP7581385B2 (https=) |
| KR (2) | KR20230029480A (https=) |
| CN (1) | CN116157143A (https=) |
| AU (1) | AU2021312323A1 (https=) |
| BR (1) | BR112023000270A2 (https=) |
| CA (1) | CA3184717A1 (https=) |
| CL (1) | CL2023000087A1 (https=) |
| CO (1) | CO2023000097A2 (https=) |
| IL (1) | IL299701A (https=) |
| MX (1) | MX2023000303A (https=) |
| PE (1) | PE20231841A1 (https=) |
| TW (2) | TWI801942B (https=) |
| WO (1) | WO2022018186A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023000303A (es) | 2020-07-22 | 2023-02-09 | Novo Nordisk As | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. |
| WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| UY40349A (es) * | 2022-07-13 | 2024-01-31 | Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd | Agonista dual de glp-1/gip, método de preparación y uso del mismo |
| TW202421645A (zh) | 2022-11-25 | 2024-06-01 | 丹麥商諾佛 儂迪克股份有限公司 | 如ｇｌｐ—１之肽治療劑的口服投與 |
| CN117646017A (zh) * | 2023-11-02 | 2024-03-05 | 中国人民解放军海军军医大学 | Gip/glp-1双激动剂多肽编码基因、及其重组乳酸菌和应用 |
| AR134436A1 (es) * | 2023-11-22 | 2026-01-14 | Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd | Uso de un agonista dual glp-1r / gipr en la fabricación de un medicamento veterinario |
| JP7755031B2 (ja) | 2023-11-30 | 2025-10-15 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬 |
| WO2025133045A1 (en) | 2023-12-22 | 2025-06-26 | Novo Nordisk A/S | Fermentation process |
| TW202535911A (zh) * | 2024-01-12 | 2025-09-16 | 大陸商杭州中美華東製藥有限公司 | 長效glp-1/gip雙激動劑的藥物組合物 |
| WO2025176999A2 (en) * | 2024-02-23 | 2025-08-28 | Ip2Ipo Innovations Limited | Novel compounds |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2300035T3 (en) | 2008-06-17 | 2015-11-16 | Univ Indiana Res & Tech Corp | Mixed GIP-based agonists for the treatment of metabolic diseases and obesity |
| CN102325539A (zh) | 2008-12-19 | 2012-01-18 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰高血糖素超家族肽前药 |
| CN102300580A (zh) | 2008-12-19 | 2011-12-28 | 印第安纳大学研究及科技有限公司 | 二肽连接的药剂 |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| EP2512518A1 (en) | 2009-12-16 | 2012-10-24 | Novo Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| RU2580317C2 (ru) | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
| EP2588127A4 (en) | 2010-06-24 | 2014-06-11 | Univ Indiana Res & Tech Corp | DIPEPTIDE-NETWORKED MEDICAL ACTIVE SUBSTANCES |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| SG191252A1 (en) * | 2010-12-22 | 2013-07-31 | Marcadia Biotech Inc | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| US8507428B2 (en) | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| WO2012167744A1 (en) | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| EP3542790B1 (en) * | 2012-03-22 | 2023-09-13 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
| JP6228187B2 (ja) | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| JP6517690B2 (ja) | 2012-06-20 | 2019-05-22 | ノヴォ ノルディスク アー／エス | ペプチド及び送達剤を含む錠剤製剤 |
| HRP20180936T1 (hr) | 2012-06-21 | 2018-12-14 | Indiana University Research And Technology Corporation | Analozi glukagona koji pokazuju aktivnost prema receptoru za gip |
| HK1211232A1 (en) | 2012-12-21 | 2016-05-20 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| CN105324125A (zh) | 2013-03-15 | 2016-02-10 | 印第安纳大学研究及科技有限公司 | 具有长效的前体药物 |
| JP6672140B2 (ja) * | 2013-05-02 | 2020-03-25 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１化合物の経口投薬 |
| LT3004155T (lt) | 2013-05-28 | 2021-12-27 | Takeda Pharmaceutical Company Limited | Peptidų junginys |
| HK1226084A1 (zh) | 2013-08-16 | 2017-09-22 | Medimmune Limited | 用於治疗糖尿病的gip和glp-1受体双重激动剂 |
| WO2015035419A1 (en) | 2013-09-09 | 2015-03-12 | Hoffmann-La Roche Inc. | Dosages of gip/glp-1 co-agonist peptides for human administration |
| MX2016005556A (es) * | 2013-11-06 | 2016-07-15 | Zealand Pharma As | Compuestos agonistas duales de gip-glp-1 y procedimientos. |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| TW201625670A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| GB2528436A (en) | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
| WO2016049174A1 (en) | 2014-09-24 | 2016-03-31 | Indiana University Research And Technology Corporation | Lipidated amide-based insulin prodrugs |
| WO2016077220A1 (en) | 2014-11-10 | 2016-05-19 | Mb2 Llc | Gip/glp-1 co-agonist peptides for human administration |
| JP2018012644A (ja) | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
| JO3575B1 (ar) | 2015-01-09 | 2020-07-05 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| US20170112897A1 (en) | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
| WO2017204219A1 (ja) | 2016-05-24 | 2017-11-30 | 武田薬品工業株式会社 | ペプチド化合物 |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| JOP20190211A1 (ar) | 2017-03-31 | 2019-09-15 | Takeda Pharmaceuticals Co | ببتيد منشط لمستقبل gip |
| PL3746111T3 (pl) | 2018-02-02 | 2024-01-15 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową |
| KR102379958B1 (ko) | 2018-05-04 | 2022-04-01 | 노보 노르디스크 에이/에스 | Gip 유도체 및 이의 용도 |
| EP3826662B9 (en) | 2018-07-23 | 2025-02-19 | Eli Lilly and Company | Method of using a gip/glp1 co-agonist for diabetes |
| CN120754229A (zh) | 2018-07-23 | 2025-10-10 | 伊莱利利公司 | 使用gip/glp1共激动剂用于治疗的方法 |
| CN112469731B (zh) | 2018-07-23 | 2024-11-29 | 伊莱利利公司 | Gip/glp1共激动剂化合物 |
| MX2021012277A (es) * | 2019-04-11 | 2021-11-12 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Agonista multireceptor y uso medico del mismo. |
| CN110642935A (zh) | 2019-09-25 | 2020-01-03 | 成都奥达生物科技有限公司 | 一种替瑞帕肽类似物 |
| CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| MX2023000303A (es) | 2020-07-22 | 2023-02-09 | Novo Nordisk As | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. |
-
2021
- 2021-07-22 MX MX2023000303A patent/MX2023000303A/es unknown
- 2021-07-22 IL IL299701A patent/IL299701A/en unknown
- 2021-07-22 US US17/383,192 patent/US20220177538A1/en not_active Abandoned
- 2021-07-22 KR KR1020217034342A patent/KR20230029480A/ko not_active Ceased
- 2021-07-22 PE PE2023000026A patent/PE20231841A1/es unknown
- 2021-07-22 TW TW110126883A patent/TWI801942B/zh active
- 2021-07-22 BR BR112023000270A patent/BR112023000270A2/pt unknown
- 2021-07-22 US US18/017,041 patent/US20230272029A1/en active Pending
- 2021-07-22 TW TW111150185A patent/TW202315883A/zh unknown
- 2021-07-22 CA CA3184717A patent/CA3184717A1/en active Pending
- 2021-07-22 JP JP2022577750A patent/JP7581385B2/ja active Active
- 2021-07-22 WO PCT/EP2021/070485 patent/WO2022018186A1/en not_active Ceased
- 2021-07-22 CN CN202180059832.9A patent/CN116157143A/zh active Pending
- 2021-07-22 EP EP21749558.9A patent/EP4185607A1/en active Pending
- 2021-07-22 AU AU2021312323A patent/AU2021312323A1/en active Pending
- 2021-07-22 KR KR1020217034294A patent/KR102446310B1/ko active Active
-
2022
- 2022-01-12 US US17/574,079 patent/US11779648B2/en active Active
- 2022-11-04 US US17/980,990 patent/US20230120597A1/en not_active Abandoned
-
2023
- 2023-01-05 CO CONC2023/0000097A patent/CO2023000097A2/es unknown
- 2023-01-09 CL CL2023000087A patent/CL2023000087A1/es unknown
-
2024
- 2024-10-24 JP JP2024187587A patent/JP2025020197A/ja active Pending